Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

iseases, including SJIA[5]. ACZ885 works by neutralizing IL-1 beta for a sustained period of time, therefore inhibiting inflammation.

ACZ885 is currently approved in the US and other countries for a different disease state.

DisclaimerThe foregoing release contains forward-looking statements that can be identified by terminology such as "can," "on track," "potentially," "will," "planned," "may," "committed," "potential," or similar expressions, or by express or implied discussions regarding potential new indications or labeling for ACZ885 or regarding potential future revenues from ACZ885. You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with ACZ885 to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that ACZ885 will be submitted or approved for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that ACZ885 will achieve any particular levels of revenue in the future. In particular, management's expectations regarding ACZ885 could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; unexpected manufacturing issues, the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... SAN DIEGO, Aug. 29, 2014  Pfenex Inc. ... in the development of high-value and difficult to ... business update and reported financial results for the ... "With the successful completion of our initial public ... advance our biosimilar product candidates, derived from our ...
(Date:8/29/2014)... but one of the most promising technologies for future ... light (photons) instead of electrons. First, it is necessary ... photons and control their direction. Researchers around the world ... control, but now scientists at the Niels Bohr Institute ... emitted one at a time and in a particular ...
(Date:8/29/2014)... York (PRWEB) August 29, 2014 ... at $5.6 billion in 2019. It is expected ... 2013 to 2019, and was valued at $1.8 ... published by Transparency Market Research. , For more ... http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, titled ...
(Date:8/29/2014)... York (PRWEB) August 29, 2014 According to ... Orthobiologics Market” the global orthobiologics market was valued at USD ... market worth USD 5,519.9million in 2019at a CAGR of 5.9% ... aged 50 years and above is afflicted by bone and ... by the year 2020. This has and will continue to ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... China, Jan. 31 /Xinhua-PRNewswire/ -- WuXi PharmaTech ... acquisition of AppTec Laboratory,Services, Inc., a US-based ... industries. AppTec offers testing, contract research and,development, ... highly,differentiated, fully integrated platform., (Logo: ...
... Pharmaceuticals,Inc. (Nasdaq: AMLN ) will be presenting at ... in New York on,Wednesday, February 6, 2008 at 1:00 ... Vice President, Finance and Chief Financial Officer of,Amylin Pharmaceuticals, ... presentation and breakout session will be webcast, and a,recording ...
... International,Inc. (Nasdaq: CHDX ) a leading independent ... the People,s Republic of China,announced that it intends ... ended December 31, 2007, on Friday, February 8, ... conference call on Friday,February 8, 2008 at 10:00 ...
Cached Biology Technology:WuXi PharmaTech Completes Acquisition of AppTec 2Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Third Quarter Results on Friday, February 8, 2008 2Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Third Quarter Results on Friday, February 8, 2008 3
(Date:8/29/2014)... Davis have made some surprising discoveries about the ... immunodeficiency virus (SIV), the team found that specialized ... early responders to viral invasion and are the ... called interleukin-1 beta (IL-1β). , Though aimed ... of the gut epithelium that provides a barrier ...
(Date:8/29/2014)... (Aug. 29, 2014) Scientists at the Barshop Institute ... of Medicine at the UT Health Science Center at ... the tissues of the longest-lived rodent, the naked mole ... the cells of naked mole rats protects and alters ... damaged and obsolete proteins. , The factor also protects ...
(Date:8/29/2014)... about what genetic changes transform wild animals into domesticated ... is a University of Montana assistant professor, has made ... of the brain and the nervous system were particularly ... 28 in Science and gives answers to ... ., The domestication of animals and plants, a prerequisite ...
Breaking Biology News(10 mins):The early cost of HIV 2Factor in naked mole rat's cells enhances protein integrity 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... NY, September 4, 2012The use of RNA in nanotechnology ... development of new therapeutic compounds. Key technical challenges remain, ... use of RNA molecules in nanotechnology approaches are presented ... , a peer-reviewed journal from Mary Ann Liebert, ...
... appliances in Spain are processed out of the Integrated ... of Salamanca exposes how many manufacturers are not registered ... According to the European directive on waste electrical ... the waste they generate during their activity until reaching ...
... fungal species, called , Hebelomagriseopruinatum , has now officially ... whose name can be translated into ,the grey-dewy tear ... mushroom-hunting tour headed by postdoc Jacob Heilman-Clausen from the ... 2009, postdoc Jacob Heilman-Clausen from the Center for Macroecology, ...
Cached Biology News:More than 70% of electronic waste management is uncontrolled 2More than 70% of electronic waste management is uncontrolled 3New Danish fungal species discovered 2
Request Info...
...
Request Info...
Agarose-LE, 500 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: